Clinical trial
Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?
NCT07201701 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?
- Lead sponsor
- Hospices Civils de Lyon
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- December 1, 2025
- Completion date
- April 1, 2028
- Enrollment
- 45 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.